Roche disclosed a program cut after a futility analysis ended a phase 2 fibrosis/inflammation program tied to a Kiniksa asset the company had acquired; Roche said no new safety signals appeared but the study was unlikely to meet efficacy goals. Separately, Roche reported a CHF 579 million negative impact in China during 2025 from pricing reforms but told investors it expects those headwinds to ease in 2026 and to disappear by 2027. The development and financial updates came alongside a broader portfolio review that included phasing out early programs and focusing on high‑value platforms such as NGS and core diagnostics. Management highlighted the company’s ongoing commitment to its Port Delivery Platform and other strategic priorities despite pipeline pruning. The twin disclosures underscore how pharmas balance portfolio optimization with geographic pricing pressures; companies will likely prioritize late‑stage assets and scalable diagnostic platforms where reimbursement dynamics are clearer.